Targeting Multiple Cancer Antigens The majority of solid tumor cancers are known to express antigens targeted by Titan’s products. Since many tumors express more than one antigen, Titan’s monoclonal antibodies can also be given in combination against certain cancers. Attacking the carcinoembryonic antigen CeaVac GLYPH<H23006> <20 20-50 >50 Survival Correlates with Immune Response in Phase I/II Study in Dukes’ D Colorectal Cancer (Patient Antibody Response, % Inhibition) (Median Survival, Months) 0 5 10 15 20 Indication(s) Preclinical Phase 1 Phase 2 Phase 3 Sponsor CeaVac ® Dukes' D  Colorectal Cancer TriAb ® Breast Cancer CeaVac$^{®}$/TriAb ® Non-Small Cell Lung Cancer TriAb$^{®}$/TriGem™* Small Cell Lung Cancer Monoclonal Antibod y Pr oducts Titan ACOSOG Titan RTOG CALGB SWOG Dukes' C Colorectal Cancer * Colorectal Cancer Antigen-expressing tumor cell CEA - wa e CeaVac targets the carcinoembryonic antigen (CEA), which is present on a number of cancers, including colorectal, non-small cell lung, pan- creatic and gastric cancer. CeaVac, which has demonstrated strong immune responses in clinical studies in colorectal cancer patients, is currently under investigation in a controlled Phase III trial in advanced colorectal cancer. Attacking the human milk fat globule antigen *To be initiated 2H 2002  Antigen-expressing tumor cell GD2 ganglioside Attacking the GD2 ganglioside antigen TriGem targets the GD2 ganglioside, a carbohydrate antigen that is present on a number of tumor types including melanoma, small cell lung cancer, neuroblastoma and sarcoma. TriGem is planned to be tested in combination with TriAb for small cell lung cancer. Antigen-expressing tumor cell HMFG ee TriAb GLYPH<H23006> TriAb targets the human milk fat globule (HMFG) antigen, which is present on a number of tumor types including breast, colorectal, non-small cell lung, ovarian, and pancreatic cancer. TriAb is being tested in breast cancer and also in combination with CeaVac for col- orectal and non-small cell lung cancers. TriGem GLYPH<H23008> Seven